{"DataElement":{"publicId":"4215492","version":"1","preferredName":"Biospecimen Primary Histology Subtype 2 Name","preferredDefinition":"Named histologic classification that is a secondary subtype of the primary biospecimen histology.","longName":"4191243v1.0:4214692v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"4191243","version":"1","preferredName":"Biospecimen Primary Histology Subtype","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A group forming a type within a larger type._Occurring first in time or sequence; original; of greatest rank or importance or value._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains","longName":"2859635v1.0:4265591v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2859635","version":"1","preferredName":"Biospecimen","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","longName":"C70699","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biospecimen","conceptCode":"C70699","definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66832E51-39F3-1736-E040-BB89AD4349FB","latestVersionIndicator":"Yes","beginDate":"2009-04-01","endDate":null,"createdBy":"UMLLOADER_TAVERNA","dateCreated":"2009-04-01","modifiedBy":"ONEDATA","dateModified":"2009-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4265591","version":"1","preferredName":"Subtype Histology","preferredDefinition":"A group forming a type within a larger type.:The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","longName":"C25696:C16681","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E276-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-09","modifiedBy":"ONEDATA","dateModified":"2014-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E0B589-5915-C26B-E040-BB89AD433ADB","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4214692","version":"1","preferredName":"Biospecimen Primary Histology Subtype 2 Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"4214692v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AML M7","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2558163","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2558163","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B040-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C2E7-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AML M6","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C2FC-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AML M5a","valueDescription":"Acute Monoblastic Leukemia","ValueMeaning":{"publicId":"4265007","version":"1","preferredName":"Acute Monoblastic Leukemia","longName":"4265007","preferredDefinition":"An acute myeloid leukemia in which the monoblasts represent 80% or more of the total cellular population.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic Leukemia","conceptCode":"C7171","definition":"An acute myeloid leukemia in which the monoblasts represent 80% or more of the total cellular population.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C30A-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C323-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AM L M5","valueDescription":"Acute Monoblastic and Monocytic Leukemia","ValueMeaning":{"publicId":"4265008","version":"1","preferredName":"Acute Monoblastic and Monocytic Leukemia","longName":"4265008","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features. It usually follows an aggressive clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C32D-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C346-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AML M4","valueDescription":"Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C35A-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AML M3","valueDescription":"Childhood Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","ValueMeaning":{"publicId":"4265010","version":"1","preferredName":"Childhood Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4265010","preferredDefinition":"An acute promyelocytic leukemia occurring in children.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C7968","definition":"An acute promyelocytic leukemia with PML-RARA fusion occurring in children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C368-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C381-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"AML M2","valueDescription":"Acute Myeloid Leukemia with Maturation","ValueMeaning":{"publicId":"2836809","version":"1","preferredName":"Acute Myeloid Leukemia with Maturation","longName":"2836809","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A992-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C395-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"ALL L2","valueDescription":"L2 Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4265012","version":"1","preferredName":"L2 Acute Lymphoblastic Leukemia","longName":"4265012","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"L2 Acute Lymphoblastic Leukemia","conceptCode":"C27281","definition":"An antiquated term that refers to acute lymphoblastic leukemia with large and irregular lymphoblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C3A3-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C3BC-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"ALL L1","valueDescription":"L1 Adult Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4265014","version":"1","preferredName":"L1 Adult Acute Lymphoblastic Leukemia","longName":"4265014","preferredDefinition":"An acute lymphoblastic leukemia (current term: precursor lymphoblastic leukemia) of B-or T-cell origin which according to the FAB classification is characterized by the presence of more mature-appearing lymphoblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult L1 Acute Lymphoblastic Leukemia","conceptCode":"C27278","definition":"L1 acute lymphoblastic leukemia that occurs during adulthood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C3C9-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C3E2-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Refractory anemia with excess blasts","valueDescription":"Refractory Anemia with Excess Blasts","ValueMeaning":{"publicId":"2838712","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts","longName":"2838712v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9753-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C3F6-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary transitional cell carcinoma","valueDescription":"Micropapillary Transitional Cell Carcinoma","ValueMeaning":{"publicId":"3155847","version":"1","preferredName":"Micropapillary Transitional Cell Carcinoma","longName":"3155847","preferredDefinition":"A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micropapillary Transitional Cell Carcinoma","conceptCode":"C65182","definition":"A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"943B8AF5-8489-8068-E040-BB89AD437602","latestVersionIndicator":"Yes","beginDate":"2010-11-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C40B-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Medullary","valueDescription":"Medullary Carcinoma, Not Otherwise Specified","ValueMeaning":{"publicId":"3248489","version":"1","preferredName":"Medullary Carcinoma, Not Otherwise Specified","longName":"3248489","preferredDefinition":"A term referring to medullary carcinomas which can develop in various anatomic sites such as the thyroid gland, breast, colon, rectum, and small intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medullary Carcinoma, Not Otherwise Specified","conceptCode":"C66718","definition":"A term referring to medullary carcinomas which can develop in various anatomic sites such as the thyroid gland, breast, colon, rectum, and small intestine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B8531E-173E-F891-E040-BB89AD4324F8","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C420-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Glioblastoma multiforme","valueDescription":"Glioblastoma multiforme","ValueMeaning":{"publicId":"2831120","version":"1","preferredName":"Glioblastoma multiforme","longName":"2831120","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D4F-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C42B-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Teratocarcinoma","valueDescription":"Mixed Embryonal Carcinoma and Teratoma","ValueMeaning":{"publicId":"4265016","version":"1","preferredName":"Mixed Embryonal Carcinoma and Teratoma","longName":"4265016","preferredDefinition":"A type of germ cell cancer that usually forms in the testes (testicles).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Embryonal Carcinoma and Teratoma","conceptCode":"C3756","definition":"A germ cell tumor characterized by the presence of an embryonal carcinoma component and a teratoma component.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6837A4B-C439-8A6A-E040-BB89AD430833","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6837A4B-C452-8A6A-E040-BB89AD430833","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Anaplastic","valueDescription":"Anaplastic carcinoma","ValueMeaning":{"publicId":"2575056","version":"1","preferredName":"Anaplastic carcinoma","longName":"2575056","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F23D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-24","modifiedBy":"REEVESD","dateModified":"2014-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-1677-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Papillary","valueDescription":"Papillary","ValueMeaning":{"publicId":"2738824","version":"1","preferredName":"Papillary","longName":"2738824","preferredDefinition":"of or relating to or resembling papilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49F8B2D6-A892-712E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"JONSDOTTIRT","dateCreated":"2008-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-1681-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3300679","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"3300679","preferredDefinition":"A carcinoma arising from squamous epithelial cells. Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells. Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells. Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B126E752-C52C-5EF2-E040-BB89AD43398A","latestVersionIndicator":"Yes","beginDate":"2011-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-1696-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Prolymphocytic Leukemia","valueDescription":"Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2590867","version":"1","preferredName":"Prolymphocytic Leukemia","longName":"2590867","preferredDefinition":"PLL. A type of chronic lymphocyctic leukemia (CLL), in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolymphocytic Leukemia","conceptCode":"C3181","definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29F3-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-16A0-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Malignant trichilemmal cyst","valueDescription":"Trichilemmocarcinoma","ValueMeaning":{"publicId":"4417192","version":"1","preferredName":"Trichilemmocarcinoma","longName":"4417192","preferredDefinition":"A rare malignant tumor arising from the outer hair sheath and infundibulum on the face. It is considered the malignant counterpart of tricholemmoma. Complete surgical excision is required.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trichilemmal Carcinoma","conceptCode":"C43326","definition":"A rare malignant tumor arising from the outer hair sheath and infundibulum on the face. It is considered the malignant counterpart of tricholemmoma. Complete surgical excision is required.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF5BE1B8-2C3F-3326-E040-BB89AD435557","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF5BE1B8-2C58-3326-E040-BB89AD435557","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Large cell variant","valueDescription":"Large Cell Carcinoma Clinical Variant","ValueMeaning":{"publicId":"4417193","version":"1","preferredName":"Large Cell Carcinoma Clinical Variant","longName":"4417193","preferredDefinition":"A malignant epithelial neoplasm composed of large, atypical cells.: A form of a disease with clinical features that differ from other forms of the same disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Variant","conceptCode":"C106134","definition":"A form of a disease with clinical features that differ from other forms of the same disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF5BE1B8-2C65-3326-E040-BB89AD435557","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF5BE1B8-2C7E-3326-E040-BB89AD435557","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F46DA4A4-1663-3FBD-E040-BB89AD431BE9","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":"Curated to support CTD2 activity","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5646652","version":"1","longName":"CTD^2 (Cancer Target Discovery and Development","context":"OCG","ClassificationSchemeItems":[{"publicId":"5092552","version":"1","longName":"Approved CDEs","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Biospecimen histology subtype","type":"Preferred Question Text","description":"Biospecimen histology subtype 2","url":null,"context":"OCG"}],"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F46DE966-0EAC-E56A-E040-BB89AD4311DA","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"COOPERM","dateModified":"2017-02-07","changeDescription":"VM concept annotation complete and CDEs released. mc 10/7/16 Moved from CTD-2 to OCG Context per request by S.Jagu. mc 2/1/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}